Chromadex (NASDAQ: CDXC) is one of 188 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its peers? We will compare Chromadex to related companies based on the strength of its institutional ownership, dividends, profitability, valuation, analyst recommendations, earnings and risk.
Risk and Volatility
Chromadex has a beta of 1.37, suggesting that its stock price is 37% more volatile than the S&P 500. Comparatively, Chromadex’s peers have a beta of 1.51, suggesting that their average stock price is 51% more volatile than the S&P 500.
Insider and Institutional Ownership
6.1% of Chromadex shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 11.6% of Chromadex shares are held by company insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This is a summary of recent ratings and recommmendations for Chromadex and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Chromadex presently has a consensus price target of $7.50, indicating a potential upside of 21.36%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 11.72%. Given Chromadex’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Chromadex is more favorable than its peers.
This table compares Chromadex and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Chromadex and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Chromadex||$26.81 million||-$2.92 million||-44.14|
|Chromadex Competitors||$217.40 million||-$39.40 million||-64.85|
Chromadex’s peers have higher revenue, but lower earnings than Chromadex. Chromadex is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Chromadex beats its peers on 7 of the 12 factors compared.
Chromadex Company Profile
Chromadex Corporation and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. The Company operates through three segments: Ingredients, which develops, supplies and commercializes ingredient technologies; Core standards and contract services, which supplies phytochemical reference standards, which are small quantities of plant-based compounds used to research an array of attributes, reference materials and related contract services, and Scientific and regulatory consulting, which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage health and regulatory risks.
Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.